[Cardiovascular effects of prostacyclin].
Numerous studies have recently been devoted to the effects of prostaglandins on blood vessels. Prostacyclin (PGI2) produces relaxation of vascular smooth muscles, thereby contributing, with other vasoactive substances, to the regulation of general and local haemodynamics. Moreover, it would appear that the effects of some risk factors in atherosclerosis are mediated, at least partly, by changes in prostaglandin production. The potent vasodilator action of prostacyclin has been confirmed in man and has been investigated in some pathological conditions, such as lower limb arteriopathy, malignant arterial hypertension and coronary artery disease. The vascular effects of many therapeutic drugs are now known to be associated with their action on the biosynthesis of prostaglandins. Further studies are required to determine the role of prostaglandins, especially prostacyclin, in the pathophysiology, prevention and treatment of vascular diseases.
D000818:Animals; D001161:Arteriosclerosis / Q000209:etiology; D002319:Cardiovascular System / Q000187:drug effects*; D011464:Epoprostenol / Q000378:metabolism / Q000494:pharmacology*; D006801:Humans; D006973:Hypertension / Q000209:etiology; D011453:Prostaglandins / Q000494:pharmacology*; D011817:Rabbits; D012079:Renal Circulation / Q000187:drug effects; D012306:Risk
D011453:Prostaglandins; D011464:Epoprostenol
Effets cardio-vasculaires de la prostacycline.